| 000 | 01841 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517002236.0 | ||
| 264 | 0 | _c20160505 | |
| 008 | 201605s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.3109/10428194.2014.982636 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLu, Chieh-Sheng | |
| 245 | 0 | 0 |
_aDiffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cJul 2015 |
||
| 300 |
_a2047-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aOrgan Specificity |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aChen, Jia-Hong | |
| 700 | 1 | _aHuang, Tzu-Chuan | |
| 700 | 1 | _aWu, Yi-Ying | |
| 700 | 1 | _aChang, Ping-Ying | |
| 700 | 1 | _aDai, Ming-Shen | |
| 700 | 1 | _aChen, Yeu-Chin | |
| 700 | 1 | _aHo, Ching-Liang | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 56 _gno. 7 _gp. 2047-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428194.2014.982636 _zAvailable from publisher's website |
| 999 |
_c24340898 _d24340898 |
||